(Q34214850)

31 July 2017

1 reference

title

STI571: a gene product-targeted therapy for leukemia (English)

1 reference

31 July 2017

1 reference

1 reference

Mauro MJ

1

1 reference

31 July 2017

Druker BJ

series ordinal

2

1 reference

31 July 2017

publication date

1 May 2001

1 reference

31 July 2017

published in

Current Oncology Reports

1 reference

31 July 2017

volume

3

1 reference

31 July 2017

issue

3

1 reference

31 July 2017

page(s)

223-227

1 reference

Structural requirements for function of the Crkl adapter protein in fibroblasts and hematopoietic cells

31 July 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11912-001-0054-Z

In vitro transformation of immature hematopoietic cells by the P210 BCR/ABL oncogene product of the Philadelphia chromosome

21 January 2018

1 reference

12 December 2020

The survival function of the Bcr-Abl oncogene is mediated by Bad-dependent and -independent pathways: roles for phosphatidylinositol 3-kinase and Raf.

1 reference

12 December 2020

Fused transcript of abl and bcr genes in chronic myelogenous leukaemia

1 reference

12 December 2020

A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia

1 reference

12 December 2020

Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome

1 reference

12 December 2020

In vivo eradication of human BCR/ABL-positive leukemia cells with an ABL kinase inhibitor

1 reference

12 December 2020

Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance.

1 reference

12 December 2020

A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity

1 reference

12 December 2020

The tyrosine kinase inhibitor STI571, like interferon-alpha, preferentially reduces the capacity for amplification of granulocyte-macrophage progenitors from patients with chronic myeloid leukemia

1 reference

12 December 2020

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

12 December 2020

Acute leukaemia in bcr/abl transgenic mice

1 reference

12 December 2020

Structural organization of the bcr gene and its role in the Ph' translocation

1 reference

12 December 2020

Bcr/Abl expression stimulates integrin function in hematopoietic cell lines

1 reference

12 December 2020

Tyrphostin-induced inhibition of p210bcr-abl tyrosine kinase activity induces K562 to differentiate

1 reference

12 December 2020

Induction of resistance to the Abelson inhibitor STI571 in human leukemic cells through gene amplification.

1 reference

12 December 2020

Selective inhibition of cell proliferation and BCR-ABL phosphorylation in acute lymphoblastic leukemia cells expressing Mr 190,000 BCR-ABL protein by a tyrosine kinase inhibitor (CGP-57148).

1 reference

12 December 2020

Lessons learned from the development of an abl tyrosine kinase inhibitor for chronic myelogenous leukemia

1 reference

12 December 2020

Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine

1 reference

12 December 2020

Initiation of deregulated growth of multipotent progenitor cells by bcr-abl in vitro

1 reference

12 December 2020

The diversity of BCR-ABL fusion proteins and their relationship to leukemia phenotype

1 reference

12 December 2020

Blockade of the Bcr-Abl kinase activity induces apoptosis of chronic myelogenous leukemia cells by suppressing signal transducer and activator of transcription 5-dependent expression of Bcl-xL

1 reference

12 December 2020

The tyrosine kinase inhibitor CGP57148B selectively inhibits the growth of BCR-ABL-positive cells

1 reference

12 December 2020

Inhibition of the ABL kinase activity blocks the proliferation of BCR/ABL+ leukemic cells and induces apoptosis.

1 reference

12 December 2020

Role of alpha1 acid glycoprotein in the in vivo resistance of human BCR-ABL(+) leukemic cells to the abl inhibitor STI571

1 reference

12 December 2020

CGP 57148, a tyrosine kinase inhibitor, inhibits the growth of cells expressing BCR-ABL, TEL-ABL, and TEL-PDGFR fusion proteins

1 reference

12 December 2020

Blocking of EGF-dependent cell proliferation by EGF receptor kinase inhibitors

1 reference

12 December 2020

Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining

1 reference

12 December 2020

Localization of the c-abl oncogene adjacent to a translocation break point in chronic myelocytic leukaemia

1 reference

12 December 2020

Lymphosarcoma: virus-induced thymic-independent disease in mice

1 reference

12 December 2020

CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs

1 reference

12 December 2020

Efficacy of STI571, an abl tyrosine kinase inhibitor, in conjunction with other antileukemic agents against bcr-abl-positive cells.

1 reference

12 December 2020

Favorable therapeutic index of a p210(BCR-ABL)-specific tyrosine kinase inhibitor; activity on lineage-committed and primitive chronic myelogenous leukemia progenitors

1 reference

12 December 2020

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

12 December 2020

Tyrphostin induced growth inhibition: correlation with effect on p210bcr-abl autokinase activity in K562 chronic myelogenous leukemia

1 reference

12 December 2020

10.1007/S11912-001-0054-Z

Identifiers

DOI

1 reference

Dimensions Publication ID

31 July 2017

1011431315

0 references

1 reference